FLT3 inhibitors in the treatment of AML

Farhad Ravandi

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Share this video  
Similar topics
Related videos
1:57
The state of CAR T-cell products today
Nitin Jain
2:28
Updates on the survival rates of MLL treatments
Rob Pieters
1:28
Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Nitin Jain
1:26
Future directions for MLL therapy
Rob Pieters
2:42
iFCG yields unprecedented MRD negativity in CLL
Nitin Jain
Acute Myeloid Leukemia, Leukemia
Azacitidine, Crenolanib, Gilteritinib, Midostaurin, Quizartinib, Sorafenib
ESH AL 2018
Interview
4th May 2018
More from Farhad Ravandi
Treating acute myeloid leukemia with VALOR – vosaroxin in combination with cytarabine
Decitabine dosing regimens in older AML patients: 5-day vs. 10-day, is there a difference?
Ruxolitinib plus decitabine in post-MPN AML
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals